T-Cell-Depleted PBSCT from Partially Matched Donors for High-Risk Leukemia

Phase 2, open-label, single-arm trial of CD34+ selected donor cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML) and 2 more, sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Incidence of graft failure at 100 days, Incidence of acute and chronic graft-vs-host disease at 100 days and 3 more. Status: terminated.